Immunotec Reports 65% European Sales Growth to $26.9 Million in First Nine Months of 2026

Immunotec reported $26.9 million in European network sales for the first nine months of 2026, a 65% increase from $16.3 million in the same period of 2024, according to EIN Presswire. The company, founded in 1996 and headquartered in The Woodlands, sells nutritional products including its Immunocal whey protein isolate through independent consultants.

Immunotec's European Sales and Market Expansion

Across its 20 European markets, Immunotec's European share of total company revenue climbed from 14.4% to 21.4%. Expansion into 11 additional European markets drove growth: network sales in those newer markets rose from approximately $120,000 in 2024 to $3.8 million in 2026 for the January–August period, more than 31 times the earlier level.

September 2026 was the strongest sales month on record for those markets, at 3.1 times the level recorded a year earlier, and active customers increased more than tenfold over the two-year period. Established European markets accounted for approximately 54% of reported incremental regional growth, while newer markets contributed 46%.

"What's particularly exciting about our growth is that it's coming from multiple directions," said Mauricio Domenzain, Chief Executive Officer of Immunotec. "We're strengthening established markets, building momentum in new ones and creating opportunities for more people to experience our products and business opportunity."

Immunotec's Financial Results From 2023 to 2025

According to akta.pro company records, Immunotec has one funding round on record, a post-IPO equity round in May 2017 with one investor. The company's revenue increased from $145 million in 2023 to $190 million in 2025, while EBITDA grew from $15.0 million to $24.5 million over the same period, the report said. Gross margin improved from 76.1% to 77.3%, and cash conversion strengthened from 20% in 2024 to 45% in 2025.

"Growth is meaningful when it creates lasting value," said Luis Ascencio, Chief Financial Officer of Immunotec. "We've focused on building the financial strength and operational discipline needed to scale responsibly."

Immunotec's Recent Award Recognition

Immunotec won two Gold Globee awards in November 2026, including Best of Category honors for global growth and for Immunocal, EIN Presswire reported. In October 2026, the company won a Gold Globee Award for Achievement in Research & Development; it has invested over $25 million in research, published 92 papers and holds 81 patents, including recent grants for autism and schizophrenia, according to the same outlet.

What Comes Next for Immunotec

Immunotec serves customers and independent consultants across 31 global markets, and its 2026 performance follows the financial improvement recorded from 2023 to 2025.